Radiomètre hyperfréquence La détection de l’émission propre constitue a de ce rayonnement dans le plasma dépend de la distribution de l’indice de réfraction. donné lieu à peu de recherches, ou du moins à peu de publications (Letarte. J Letarte’s 83 research works with citations and reads, including: Resultats du traitement a long terme d’un garcon de 7 ans dont l’activite ornithine .. to evaluate the cardiac dimensions and various indices of myocardial function . Suivre. Dominic Letarte Adresse e-mail validée de – Page d’accueil E Merlo, D Letarte, G Antoniol F Gauthier, D Letarte, T Lavoie, E Merlo.
|Published (Last):||25 November 2009|
|PDF File Size:||17.19 Mb|
|ePub File Size:||13.76 Mb|
|Price:||Free* [*Free Regsitration Required]|
In a small cohort of patients, testosterone replacement with topical gel has been shown d normalize testosterone levels and to improve symptoms A phase iii study in advanced ALK -positive nsclc progressing on a first-line platinum-based doublet compared crizotinib with standard second-line chemotherapy using pemetrexed or docetaxel profile Hypogonadism occurs quite commonly in patients with advanced cancer, and indlce is often underdiagnosed and rarely treated Table ii describes the key toxicities and suggests parameters to monitor.
Importantly, although gastrointestinal effects are frequently seen with crizotinib, they tend to improve over time and grade 3 or 4 ae s are rare 8. If co-administration of such drugs is unavoidable, monitoring should occur more frequently. Given that a large number of patients treated with crizotinib are young adults indlce will be on therapy for relatively long periods of time, such symptoms can be even more distressing.
Managing treatment–related adverse events associated with Alk inhibitors
The exact mechanism of this phenomenon is not known. Peripheral Edema Peripheral edema occurs in up to one third dee patients taking crizotinib, being the main cumulative effect of this agent Table i. Proactive management of ae s helps to optimize the therapeutic index of targeted therapies and enhances quality of life for patients. In non-small-cell lung cancer nsclcthe shift was first seen with the discovery that mutations in the epidermal growth factor receptor predicted responsiveness to epidermal growth factor receptor idnice kinase inhibitors.
Patients on treatment for more than 6 letafte did not have any new ae s or issues related to prolonged exposure 8. Journal List Curr Oncol v. Although QT prolongation was observed in patients on crizotinib, no associated arrhythmias were observed That study demonstrated significant improvements in response rate and progression-free survival in favour of crizotinib, but no overall survival benefit was observed, presumably because of crossover.
Gaël Letarte – Citations Google Scholar
Because of the high incidence of baseline pulmonary disease, radiation-related changes, infectious complications, and presence of progressive malignancy, a diagnosis of drug-induced pneumonitis can be difficult to make in lung cancer patients. However, in patients with unexplained letarts symptoms, crizotinib-induced pneumonitis has to be considered in the differential diagnosis. Patients with ALK rearrangements tend to be younger at diagnosis median age: Table iii describes management of QT prolongation.
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Toxicity ctcae grade Toxicity description Dosing Hematologic toxicity Grade 3 anc: A practical question about ability to drive often comes up at crizotinib start.
The recommended dose of crizotinib is mg taken orally twice daily. Activity and safety of crizotinib in indce with ALK-positive non-small-cell lung cancer: Grades 1 and 2 nausea or vomiting were commonly seen in the clinical trials Table i. Transaminase elevations are usually reversible, and patients are typically able to resume treatment at the same or a lower dose.
Heart rate decrease is a pharmacodynamic effect of crizotinib, averaging 2.
Demers, Battinelli, & Letarte, Local Group Carbon Star Survey. VI. NGC
Ophthalmologic assessment was carefully performed in the profile study, and no clinically meaningful changes were found. Management of constipation includes dietary modification and standard laxatives. For many patients, taking crizotinib with food is a helpful strategy for alleviating the nausea 8. Isolated central nervous system progression on crizotinib: The newer agents are generally more potent than crizotinib xe structurally distinct.
Find articles by N. Temporary discontinuation or dose reduction because of a hepatic adverse event occurred in 5. Withhold until recovery to grade 2 ineice lower.
Inanaplastic lymphoma kinase ALK gene rearrangements were identified in nsclc 12. Gastrointestinal Effects The main gastrointestinal effects of crizotinib include nausea, diarrhea, vomiting, and constipation. In patients who have symptoms of hypogonadism, serum testosterone should be checked.
Food and Drug Administration and Health Canada. Final efficacy results from OAMg, a randomized phase ii study evaluating MetMAb or placebo in combination with erlotinib in advanced nsclc [abstract ] J Clin Oncol.
In patients treated on profilea visual symptom assessment questionnaire was completed on day 1 leharte each cycle.